Overall, our study revealed the significance of FTO‐FOS‐IGF2BP1/2 as a prospective biomarker panel for GC metastatic prediction and elucidated the regulatory mechanism of the reduced metastasis in EBVaGC from the perspective of epigenetics. The gene discussed is FOS; the disease is gastric cancer.